Progressive Care Reports Full Year 2021 Financial Results Highlighted by $38.9 Million in Revenue
Progressive Care Inc. (OTCQB: RXMD) reported key financial and operational results for 2021, with revenue reaching $38.9 million, including $4.3 million from COVID-19 testing. The gross margin improved to 26%, and EBITDA increased to $167,000. The company expanded its pharmacy services and strengthened its position in the 340B sector, signing eight new contracts. Management expresses optimism for future growth, especially with the pending Nasdaq uplisting, aiming for enhanced shareholder value.
- Revenue increased to $38.9 million in 2021.
- Gross margin rose to 26% from 23% in 2020.
- EBITDA increased to $167,000 from $7,000 in 2020.
- 10% increase in prescription revenue in Q4 2021 compared to Q3 2021.
- None.
Positioned for Accelerated Revenue Growth and to Become an SEC Reporting Company in 2022
Miami, FL, March 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Progressive Care Inc. (OTCQB: RXMD) (the “Company”), a personalized healthcare services and technology provider, today announced financial and operational results for the year ended December 31, 2021.
Key Financial Highlights for Year Ended December 31, 2021
• Revenue at
- COVID-19 testing revenue of approximately
- ClearMetrX TPA and pharmacy dispensing revenue related to 340B earned
• Gross margin increased to
• EBITDA increased to
• Cash balance of
Business Highlights for the Year Ended December 31, 2021
• Re-implemented upgraded pharmacy software system
• Expanded COVID-19 business into corporate-focused services and institutional clients
• Strengthened reputation in the 340B sector by adding eight new contracts
• Filed initial S-1 registration statement
• Submitted application for uplisting to Nasdaq
Q4 2021 Reflected a Positive Bounce Back in Business
• Increase of
• Increase of
Subsequent Events
• Filed Form 10-12G registration statement with the SEC
Management Commentary
Alan Jay Weisberg, Chairman and Chief Executive Officer of Progressive Care, commented, “In 2021 our team overcame many obstacles, macro and company-specific, and we exited the year in a much stronger position regarding our business and capital markets strategy. Our team was able to complete complex implementation of the pharmacy system and get back to growing the pharmacy business, successfully achieve significant revenue from COVID-19 services and position itself to become an SEC reporting company.”
Mr. Weisberg, continued, “We believe that our 4th Quarter 2021 performance and activities have provided us with good momentum, and we expect 1st Quarter 2022 performance to reflect that. Again, I find it important to communicate our company’s mission - the healthier we make our patients, the more successful our business will be, and we will not lose sight of that vision, with the goal of enhancing and creating more value for our shareholders. Progressive Care believes that investments in technology and talent will provide the type of value the company and its shareholders deserve.”
Mr. Weisberg concluded, “We expect that our planned uplist to Nasdaq, once completed, will have an immediate and positive impact on growth of the company, enabling us to increase our operational pace by having access to institutional capital and to pursue the businesses we think will help us roll out our services nationwide at a faster pace. Meanwhile, we will do our part by staying on a steady course of growing our business. We strongly believe that optimism around Progressive Care will soon begin to be reflected in the share price of our stock.”
Progressive Care Inc.
Progressive Care Inc. (OTCQB: RXMD), through its subsidiaries, is a Florida health services organization and provider of prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management.
For more information about Progressive Care, please visit the company’s website.
Connect and stay in touch with us on social media:
Progressive Care Inc.
https://www.progressivecareus.com/
https://twitter.com/ProgressCareUS
PharmCoRx
ClearMetrX
https://www.facebook.com/clearmetrx/
Forward-Looking Statements:
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance, and opportunities that involve substantial risks and
uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target,” “intend” and “expect” and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.
Public Relations Contact:
Carlos Rangel
carlosr@pharmcorx.com
Investor Relations Contact:
ClearThink Capital
nyc@clearthink.capital
p917-658-7878
FAQ
What were Progressive Care's financial results for 2021?
How much revenue did Progressive Care generate from COVID-19 testing?
What is the significance of the Nasdaq uplisting for RXMD?
How did prescription revenue change in Q4 2021 for RXMD?
